RESMED INC
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 6/30/26
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 659 | 9.1 |
| Stockholders' equity | 6,585 | 90.9 |
| Total capitalization | 7,245 | 100.0 |
144,252,306 shares outstanding at 10 August 2026 (cover page of the 10-K filed 13 August 2026).
LONG-TERM DEBT 6/30/26
| ($ millions) | Amount |
|---|---|
| Long-term debt, incl. current maturities | 399 |
| Short-term borrowings / commercial paper | 260 |
CAPITAL STOCK 6/30/26
| Common shares authorized | 350,000,000 |
| Common shares issued | 191,037,523 |
| Treasury shares | 46,798,043 |
| Par or stated value per share ($) | 0.004 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 8/10/26 | 144,252,306 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2026 | 2.40 | 23.0 |
| 2025 | 2.12 | 22.3 |
| 2024 | 1.92 | 27.7 |
| 2023 | 1.76 | 28.9 |
| 2022 | 1.68 | 31.7 |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware.
BUSINESS: Classified by the SEC under Standard Industrial Classification 3841, Surgical & Medical Instruments & Apparatus. Large accelerated filer. Principal executive office: 9001 Spectrum Center Blvd., San Diego, CA 92123. Fiscal year ends June 30. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 6/30/26 | 6/30/25 | 6/30/24 |
|---|---|---|---|
| Revenues | 5,653 | 5,146 | 4,685 |
| Cost of revenues | 2,202 | 2,091 | 2,030 |
| Gross profit | 3,452 | 3,055 | 2,655 |
| Research and development | 378 | 331 | 308 |
| Selling, general and administrative | 1,120 | 993 | 917 |
| Depreciation and amortization | 201 | 198 | 177 |
| Operating income | 1,887 | 1,685 | 1,320 |
| Income before income taxes | 1,919 | 1,678 | 1,265 |
| Income taxes | 396 | 277 | 244 |
| Net income | 1,523 | 1,401 | 1,021 |
| Earned per share, diluted ($) | 10.43 | 9.51 | 6.92 |
| Dividends per share ($) | 2.40 | 2.12 | 1.92 |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 6/30/26 | 6/30/25 |
|---|---|---|
| Cash and equivalents | 1,469 | 1,209 |
| Receivables, net | 1,036 | 939 |
| Inventories | 946 | 928 |
| Total current assets | 4,325 | 3,506 |
| Property, plant and equipment, net | 582 | 551 |
| Goodwill | 2,910 | 3,047 |
| Total assets | 8,966 | 8,174 |
| Total current liabilities | 1,395 | 1,019 |
| Total liabilities | 2,381 | 2,207 |
| Stockholders' equity | 6,585 | 5,968 |
| Total liabilities and equity | 8,966 | 8,174 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6/30/26 | 5,653 | 1,887 | 1,523 | 26.9 | 10.43 | 2.40 | 1,806 | 156 | 1,650 | 8,966 | 2,381 | 659 | 6,585 | 23.1 | 0.10 |
| 6/30/25 | 5,146 | 1,685 | 1,401 | 27.2 | 9.51 | 2.12 | 1,752 | 90 | 1,662 | 8,174 | 2,207 | 668 | 5,968 | 23.5 | 0.11 |
| 6/30/24 | 4,685 | 1,320 | 1,021 | 21.8 | 6.92 | 1.92 | 1,401 | 99 | 1,302 | 6,872 | 2,008 | 707 | 4,864 | 21.0 | 0.15 |
| 6/30/23 | 4,223 | 1,132 | 898 | 21.3 | 6.09 | 1.76 | 693 | 120 | 574 | 6,752 | 2,622 | 1,441 | 4,130 | 21.7 | 0.35 |
| 6/30/22 | 3,578 | 1,000 | 779 | 21.8 | 5.30 | 1.68 | 351 | 135 | 216 | 5,096 | 1,735 | 775 | 3,361 | 23.2 | 0.23 |
| 6/30/21 | 3,197 | 904 | 475 | 14.8 | 3.24 | 1.56 | 737 | 103 | 634 | 4,728 | 1,842 | 655 | 2,886 | 16.4 | 0.23 |
| 6/30/20 | 2,957 | 810 | 622 | 21.0 | 4.27 | 1.56 | 802 | 95 | 707 | 4,587 | 2,090 | 1,176 | 2,497 | 24.9 | 0.47 |
| 6/30/19 | 2,607 | 579 | 405 | 15.5 | 2.80 | 1.48 | 459 | 69 | 390 | 4,108 | 2,035 | 1,271 | 2,072 | 19.5 | 0.61 |
| 6/30/18 | 2,340 | 542 | 316 | 13.5 | 2.19 | 1.40 | 505 | 63 | 442 | 3,064 | 1,005 | 281 | 2,059 | 15.3 | 0.14 |
| 6/30/17 | 2,067 | 426 | 342 | 16.6 | 2.40 | 1.32 | 414 | 62 | 352 | 3,468 | 1,508 | 1,079 | 1,960 | 17.5 | 0.55 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
RESMED INC
CIK 943819 · EIN 98-0152841
PRINCIPAL OFFICE:
9001 Spectrum Center Blvd., San Diego, CA 92123
Tel.: 8587462400
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
3841 · Surgical & Medical Instruments & Apparatus
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 6/30/26, filed 13 August 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2026 (filed 8/13/26) · 10-K FY2025 (filed 8/8/25) · 10-K FY2024 (filed 8/9/24) · 10-K FY2023 (filed 8/11/23) · 10-K FY2022 (filed 8/12/22) · 10-K FY2021 (filed 8/17/21) · 10-K FY2020 (filed 8/13/20) · 10-K FY2019 (filed 8/8/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.